CA3080087A1 - Vaccin felin multivalent - Google Patents
Vaccin felin multivalent Download PDFInfo
- Publication number
- CA3080087A1 CA3080087A1 CA3080087A CA3080087A CA3080087A1 CA 3080087 A1 CA3080087 A1 CA 3080087A1 CA 3080087 A CA3080087 A CA 3080087A CA 3080087 A CA3080087 A CA 3080087A CA 3080087 A1 CA3080087 A1 CA 3080087A1
- Authority
- CA
- Canada
- Prior art keywords
- fcv
- feline
- capsid protein
- vaccine
- antigenic fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000282324 Felis Species 0.000 title claims abstract description 94
- 229960005486 vaccine Drugs 0.000 title claims description 119
- 238000000034 method Methods 0.000 claims abstract description 14
- 241000710929 Alphavirus Species 0.000 claims description 111
- 239000002245 particle Substances 0.000 claims description 106
- 241000714201 Feline calicivirus Species 0.000 claims description 104
- 239000012634 fragment Substances 0.000 claims description 91
- 230000000890 antigenic effect Effects 0.000 claims description 88
- 108090000565 Capsid Proteins Proteins 0.000 claims description 80
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 79
- 241000714165 Feline leukemia virus Species 0.000 claims description 71
- 108091007433 antigens Proteins 0.000 claims description 54
- 102000036639 antigens Human genes 0.000 claims description 54
- 239000000203 mixture Substances 0.000 claims description 53
- 244000052769 pathogen Species 0.000 claims description 52
- 101800001271 Surface protein Proteins 0.000 claims description 42
- 230000002163 immunogen Effects 0.000 claims description 41
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 40
- 239000000427 antigen Substances 0.000 claims description 36
- 230000001717 pathogenic effect Effects 0.000 claims description 36
- 241000701087 Felid alphaherpesvirus 1 Species 0.000 claims description 33
- 241000711798 Rabies lyssavirus Species 0.000 claims description 32
- 241000701915 Feline panleukopenia virus Species 0.000 claims description 29
- 206010014611 Encephalitis venezuelan equine Diseases 0.000 claims description 27
- 108090000288 Glycoproteins Proteins 0.000 claims description 27
- 102000003886 Glycoproteins Human genes 0.000 claims description 27
- 208000002687 Venezuelan Equine Encephalomyelitis Diseases 0.000 claims description 27
- 201000009145 Venezuelan equine encephalitis Diseases 0.000 claims description 27
- 241001647374 Chlamydia felis Species 0.000 claims description 19
- 108091006027 G proteins Proteins 0.000 claims description 13
- 102000030782 GTP binding Human genes 0.000 claims description 13
- 108091000058 GTP-Binding Proteins 0.000 claims description 13
- 230000009885 systemic effect Effects 0.000 claims description 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 230000003053 immunization Effects 0.000 claims description 5
- 241000606161 Chlamydia Species 0.000 claims description 4
- 230000006806 disease prevention Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229940031348 multivalent vaccine Drugs 0.000 abstract description 20
- 239000003223 protective agent Substances 0.000 abstract description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 109
- 241000282326 Felis catus Species 0.000 description 41
- 239000013598 vector Substances 0.000 description 25
- 241000700605 Viruses Species 0.000 description 22
- 230000002238 attenuated effect Effects 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 17
- 239000003085 diluting agent Substances 0.000 description 15
- 208000015181 infectious disease Diseases 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 238000002255 vaccination Methods 0.000 description 13
- 230000003612 virological effect Effects 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- 206010037742 Rabies Diseases 0.000 description 10
- 229930006000 Sucrose Natural products 0.000 description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 108091008146 restriction endonucleases Proteins 0.000 description 9
- 239000005720 sucrose Substances 0.000 description 9
- 241000701925 Feline parvovirus Species 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 8
- 230000028993 immune response Effects 0.000 description 8
- -1 ny Species 0.000 description 8
- 241000712461 unidentified influenza virus Species 0.000 description 8
- 108700026244 Open Reading Frames Proteins 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 241000724653 Borna disease virus Species 0.000 description 6
- 241000282465 Canis Species 0.000 description 6
- 101800001467 Envelope glycoprotein E2 Proteins 0.000 description 6
- 241000711475 Feline infectious peritonitis virus Species 0.000 description 6
- 108091061960 Naked DNA Proteins 0.000 description 6
- 241000710961 Semliki Forest virus Species 0.000 description 6
- 108700005078 Synthetic Genes Proteins 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 210000003501 vero cell Anatomy 0.000 description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 5
- 241000588779 Bordetella bronchiseptica Species 0.000 description 5
- 101900302604 Feline leukemia virus Surface protein Proteins 0.000 description 5
- 241000446432 Feline pneumovirus Species 0.000 description 5
- 101900083372 Rabies virus Glycoprotein Proteins 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 229940001442 combination vaccine Drugs 0.000 description 5
- 208000023504 respiratory system disease Diseases 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 4
- 241000713800 Feline immunodeficiency virus Species 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 101710172711 Structural protein Proteins 0.000 description 4
- 108091027544 Subgenomic mRNA Proteins 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 4
- 210000000234 capsid Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 108020005065 3' Flanking Region Proteins 0.000 description 3
- 108020005029 5' Flanking Region Proteins 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241000606660 Bartonella Species 0.000 description 3
- 241001518086 Bartonella henselae Species 0.000 description 3
- 241000446430 Canine pneumovirus Species 0.000 description 3
- 108700010070 Codon Usage Proteins 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 208000002979 Influenza in Birds Diseases 0.000 description 3
- 206010024769 Local reaction Diseases 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 101710159752 Poly(3-hydroxyalkanoate) polymerase subunit PhaE Proteins 0.000 description 3
- 101710130262 Probable Vpr-like protein Proteins 0.000 description 3
- 101710137500 T7 RNA polymerase Proteins 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 206010064097 avian influenza Diseases 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 239000013553 cell monolayer Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 241001493065 dsRNA viruses Species 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 238000000126 in silico method Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- PQHQBRJAAZQXHL-GQCOAOBCSA-N 2-(4-iodanyl-2,5-dimethoxyphenyl)ethanamine Chemical compound COC1=CC(CCN)=C(OC)C=C1[125I] PQHQBRJAAZQXHL-GQCOAOBCSA-N 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 2
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- 101710121417 Envelope glycoprotein Proteins 0.000 description 2
- 208000002613 Feline Panleukopenia Diseases 0.000 description 2
- 241000725579 Feline coronavirus Species 0.000 description 2
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010017577 Gait disturbance Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010024264 Lethargy Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108060004795 Methyltransferase Proteins 0.000 description 2
- 206010028034 Mouth ulceration Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 241000125945 Protoparvovirus Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010039424 Salivary hypersecretion Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 101710142606 Sliding clamp Proteins 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 206010000210 abortion Diseases 0.000 description 2
- 231100000176 abortion Toxicity 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 229960003971 influenza vaccine Drugs 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 208000030175 lameness Diseases 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 238000002559 palpation Methods 0.000 description 2
- 230000001769 paralizing effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 208000026451 salivation Diseases 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 101000787132 Acidithiobacillus ferridurans Uncharacterized 8.2 kDa protein in mobL 3'region Proteins 0.000 description 1
- 101000827262 Acidithiobacillus ferrooxidans Uncharacterized 18.9 kDa protein in mobE 3'region Proteins 0.000 description 1
- 101000811747 Antithamnion sp. UPF0051 protein in atpA 3'region Proteins 0.000 description 1
- 101000827607 Bacillus phage SPP1 Uncharacterized 8.5 kDa protein in GP2-GP6 intergenic region Proteins 0.000 description 1
- 101000961975 Bacillus thuringiensis Uncharacterized 13.4 kDa protein Proteins 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 101000964407 Caldicellulosiruptor saccharolyticus Uncharacterized 10.7 kDa protein in xynB 3'region Proteins 0.000 description 1
- 241000680578 Canid alphaherpesvirus 1 Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241001647378 Chlamydia psittaci Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 208000000655 Distemper Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282323 Felidae Species 0.000 description 1
- 101900316143 Feline calicivirus Capsid protein Proteins 0.000 description 1
- 101900068883 Feline leukemia virus Envelope glycoprotein Proteins 0.000 description 1
- 208000001951 Fetal Death Diseases 0.000 description 1
- 101150082239 G gene Proteins 0.000 description 1
- 241001663880 Gammaretrovirus Species 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 206010069767 H1N1 influenza Diseases 0.000 description 1
- 101000768777 Haloferax lucentense (strain DSM 14919 / JCM 9276 / NCIMB 13854 / Aa 2.2) Uncharacterized 50.6 kDa protein in the 5'region of gyrA and gyrB Proteins 0.000 description 1
- 101710121996 Hexon protein p72 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 101000607404 Infectious laryngotracheitis virus (strain Thorne V882) Protein UL24 homolog Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 101000735632 Klebsiella pneumoniae Uncharacterized 8.8 kDa protein in aacA4 3'region Proteins 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 101710141347 Major envelope glycoprotein Proteins 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 241000702625 Mink enteritis virus Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 208000009620 Orthomyxoviridae Infections Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 101100356268 Schizosaccharomyces pombe (strain 972 / ATCC 24843) red1 gene Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241000258242 Siphonaptera Species 0.000 description 1
- 101000818100 Spirochaeta aurantia Uncharacterized 12.7 kDa protein in trpE 5'region Proteins 0.000 description 1
- 101001037658 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) Glucokinase Proteins 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 208000035472 Zoonoses Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000002223 anti-pathogen Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001672 cytoproliferative effect Effects 0.000 description 1
- 230000002466 cytosuppressive effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 101150030339 env gene Proteins 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960004279 formaldehyde Drugs 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- 101150098622 gag gene Proteins 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 238000002013 hydrophilic interaction chromatography Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000001038 ionspray mass spectrometry Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019420 lymphoid neoplasm Diseases 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 208000015001 muscle soreness Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229940023146 nucleic acid vaccine Drugs 0.000 description 1
- 229940126578 oral vaccine Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 101150088264 pol gene Proteins 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 229960003127 rabies vaccine Drugs 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 238000003168 reconstitution method Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 231100000537 stillbirth Toxicity 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- UBCKGWBNUIFUST-YHYXMXQVSA-N tetrachlorvinphos Chemical compound COP(=O)(OC)O\C(=C/Cl)C1=CC(Cl)=C(Cl)C=C1Cl UBCKGWBNUIFUST-YHYXMXQVSA-N 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
La présente invention concerne de nouveaux vaccins multivalents pour les félins. La présente invention concerne également des procédés de fabrication et d'utilisation des vaccins multivalents seuls ou en combinaison avec d'autres agents protecteurs.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762599401P | 2017-12-15 | 2017-12-15 | |
| US62/599,401 | 2017-12-15 | ||
| PCT/EP2018/080106 WO2019115090A1 (fr) | 2017-12-15 | 2018-11-05 | Vaccin félin multivalent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3080087A1 true CA3080087A1 (fr) | 2019-06-20 |
Family
ID=64316488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3080087A Pending CA3080087A1 (fr) | 2017-12-15 | 2018-11-05 | Vaccin felin multivalent |
Country Status (4)
| Country | Link |
|---|---|
| JP (2) | JP7427585B2 (fr) |
| AU (2) | AU2018383915B9 (fr) |
| CA (1) | CA3080087A1 (fr) |
| WO (1) | WO2019115090A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2926813T3 (es) * | 2015-12-23 | 2022-10-28 | Intervet Int Bv | Vacuna contra el calicivirus felino |
| EP4149532A1 (fr) | 2020-05-11 | 2023-03-22 | Intervet International B.V. | Vaccin contre le coronavirus 2 du syndrome respiratoire aigu sévère félin |
| MX2023005495A (es) | 2020-11-12 | 2023-05-23 | Intervet Int Bv | Vectores recombinantes que codifican para proteinas espiculares quimericas del coronavirus y uso de los mismos. |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU783559B2 (en) * | 2000-03-09 | 2005-11-10 | Colorado State University Research Foundation | Use of recombinant antigens to determine the immune status of an animal |
| EP1326990B1 (fr) * | 2000-08-29 | 2007-09-19 | Wyeth Holdings Corporation | Encapsulation de particules de replicon de virus d'arn a chaine positive |
| US7309495B2 (en) | 2003-03-14 | 2007-12-18 | The Regents Of The University Of California | Hemorrhagic feline calicivirus |
| ES2321212T3 (es) | 2004-05-18 | 2009-06-03 | Alphavax, Inc. | Vectores alfavirus derivados de tc-83, particulas y metodos antecentes de la invencion. |
| US7306807B2 (en) * | 2004-09-13 | 2007-12-11 | Wyeth | Hemorrhagic feline calicivirus, calicivirus vaccine and method for preventing calicivirus infection or disease |
| US7850977B2 (en) | 2007-06-21 | 2010-12-14 | Alphavax, Inc. | Promoterless cassettes for expression of alphavirus structural proteins |
| ES2926813T3 (es) * | 2015-12-23 | 2022-10-28 | Intervet Int Bv | Vacuna contra el calicivirus felino |
| AU2018380582A1 (en) * | 2017-12-08 | 2020-05-07 | Intervet International B.V. | Feline calicivirus vaccine |
-
2018
- 2018-11-05 CA CA3080087A patent/CA3080087A1/fr active Pending
- 2018-11-05 JP JP2020524411A patent/JP7427585B2/ja active Active
- 2018-11-05 WO PCT/EP2018/080106 patent/WO2019115090A1/fr unknown
- 2018-11-05 AU AU2018383915A patent/AU2018383915B9/en active Active
-
2022
- 2022-07-30 AU AU2022209359A patent/AU2022209359A1/en active Pending
-
2023
- 2023-09-22 JP JP2023158724A patent/JP2023179547A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021506746A (ja) | 2021-02-22 |
| AU2018383915B2 (en) | 2023-05-25 |
| AU2018383915A1 (en) | 2020-05-14 |
| AU2022209359A1 (en) | 2022-09-29 |
| AU2018383915B9 (en) | 2023-06-01 |
| WO2019115090A1 (fr) | 2019-06-20 |
| JP7427585B2 (ja) | 2024-02-05 |
| JP2023179547A (ja) | 2023-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022209359A1 (en) | Multivalent feline vaccine | |
| JP2024001076A (ja) | 狂犬病ウイルスワクチン | |
| JP2023159325A (ja) | ネコカリシウイルスワクチン | |
| CA3080427A1 (fr) | Vaccin contre le virus de la leucemie feline | |
| US11730809B2 (en) | Multivalent feline vaccine | |
| US12076392B2 (en) | Feline leukemia virus vaccine | |
| RU2797538C2 (ru) | Поливалентная вакцина для животных семейства кошачьих | |
| RU2782350C2 (ru) | Вакцина против вируса бешенства | |
| RU2792898C2 (ru) | Вакцина против кошачьего калицивируса | |
| US20240269259A1 (en) | Rabies virus vaccine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231106 |
|
| EEER | Examination request |
Effective date: 20231106 |